Ubs Group Ag Revance Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 190,192 shares of RVNC stock, worth $488,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,192

Previous 194,153 2.04%

Holding current value

$488,793

Previous $1.71 Million 45.19%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.65 - $9.31 $18,418 - $36,876	-3,961 Reduced 2.04%	190,192 $935,000
Q4 2023 Feb 09, 2024	BUY	$5.81 - $11.2 $442,187 - $852,409	76,108 Added 64.47%	194,153 $1.71 Million
Q3 2023 Nov 09, 2023	SELL	$11.47 - $25.07 $137,410 - $300,338	-11,980 Reduced 9.21%	118,045 $1.35 Million
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $31,220 - $47,539	-1,264 Reduced 0.96%	130,025 $3.29 Million
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $1.07 Million - $2.06 Million	58,464 Added 80.28%	131,289 $4.23 Million

Q4 2022 Feb 08, 2023	SELL	$18.32 - $30.66 $182,045 - $304,668	-9,937 Reduced 12.01%	72,825 $1.34 Million
Q3 2022 Nov 10, 2022	SELL	$14.33 - $28.47 $59,426 - $118,065	-4,147 Reduced 4.77%	82,762 $2.23 Million
Q2 2022 Aug 10, 2022	SELL	$11.52 - $20.4 $27,198 - $48,164	-2,361 Reduced 2.64%	86,909 $1.2 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $57,041 - $93,730	4,615 Added 5.45%	89,270 $1.74 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $291,240 - $651,433	23,374 Added 38.14%	84,655 $1.38 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $208,792 - $268,967	8,099 Added 15.23%	61,281 $1.71 Million
Q2 2021 Aug 13, 2021	SELL	$26.8 - $31.84 $25,513 - $30,311	-952 Reduced 1.76%	53,182 $1.58 Million
Q1 2021 May 12, 2021	BUY	$24.03 - $29.97 $147,544 - $184,015	6,140 Added 12.79%	54,134 $1.51 Million
Q4 2020 Feb 11, 2021	SELL	$23.41 - $28.34 $11,962 - $14,481	-511 Reduced 1.05%	47,994 $1.36 Million
Q3 2020 Nov 12, 2020	SELL	$23.23 - $34.3 $107,973 - $159,426	-4,648 Reduced 8.74%	48,505 $1.22 Million
Q2 2020 Jul 31, 2020	BUY	$12.6 - $26.55 $156,580 - $329,936	12,427 Added 30.51%	53,153 $1.3 Million
Q1 2020 May 01, 2020	BUY	$12.46 - $27.81 $142,990 - $319,147	11,476 Added 39.23%	40,726 $603,000
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $324,731 - $561,177	27,850 Added 1989.29%	29,250 $474,000
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $1,963 - $2,850	184 Added 15.13%	1,400 $18,000
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $11,827 - $15,659	768 Added 171.43%	1,216 $19,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $29,203 - $40,360	-1,617 Reduced 78.31%	448 $9,000
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $32,569 - $41,628	-1,383 Reduced 40.11%	2,065 $52,000
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $23,442 - $28,480	854 Added 32.92%	3,448 $95,000
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $6,238 - $8,003	214 Added 8.99%	2,594 $80,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $1,129 - $1,669	46 Added 1.97%	2,380 $85,000
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $41,108 - $51,226	1,823 Added 356.75%	2,334 $64,000
Q2 2017 Aug 14, 2017	BUY	N/A	500 Added 4545.45%	511 $13,000
Q1 2017 Nov 14, 2017	BUY	N/A	11	11 $0

Others Institutions Holding RVNC

# of Institutions

214

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account